SCHEMBL10564473

SCHEMBL10564473

C[S+]([O-])c1ccc2c(c1)CCNCC2

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 12/20 0.48
▸ HTR2B P41595 11/20 0.48
▸ HTR2A P28223 1/20 0.48
▸ DRD2 P14416 1/20 0.41
▸ DRD1 P21728 1/20 0.41
▸ ADCY6 O43306 1/20 0.41
▸ ADCY3 O60266 1/20 0.41
▸ ADCY9 O60503 1/20 0.41
▸ ADCY5 O95622 1/20 0.41
▸ ADCY8 P40145 1/20 0.41
▸ ADCY7 P51828 1/20 0.41
▸ ADCY2 Q08462 1/20 0.41
▸ ADCY1 Q08828 1/20 0.41
▸ ADCY4 Q8NFM4 1/20 0.41
▸ PNMT P11086 1/20 0.40
▸ HRH3 Q9Y5N1 1/20 0.39
▸ ADRA2A P08913 1/20 0.38
▸ ADRA2B P18089 1/20 0.38
▸ ADRA2C P18825 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10351372 0.98 HTR2C (0.47) HTR2CHTR2BHTR2ADRD2DRD1
Hydrochloric Acid SCHEMBL11478357 0.88 PNMT (0.51) DRD2PNMTADRA2AADRA2BADRA2C
SCHEMBL11328613 0.80 PNMT (0.43) DRD2PNMTADRA2AADRA2BADRA2C
SCHEMBL3238935 0.76 DRD2 (0.50) DRD2HRH3
SCHEMBL10567329 0.70 ADCY6 (0.41) HTR2CHTR2BHTR2ADRD2DRD1
SCHEMBL10350533 0.70 NOTUM (0.47) HRH3
SCHEMBL21254761 0.70 CA12 (0.40) HRH3
SCHEMBL10232037 0.70 HTR2C (0.57) HTR2CHTR2BHTR2ADRD2DRD1
Hydrochloric Acid SCHEMBL10350476 0.69 ADCY6 (0.39) HTR2CHTR2BHTR2ADRD2DRD1
SCHEMBL10564212 0.69 HTR2C (0.43) HTR2CHTR2BHTR2ADRD2DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4824839-A Sulfinyl and sulfonyl substituted 2,3,4,5 tetrahydro-1H-3-benzazepines and their use in treating gastrointestinal motility disorders SMITHKLINE BECKMAN CORPORATION (US) 1989-04-25 — — US disclosed
Send feedback